Monday, April 29, 2019
TherapeuticsMD (TXMD)
Can the Early Commercial Success Eradicate the Stock Overhang?
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Assumption of Coverage with Outperform Rating and $13 Price
Target. We are assuming coverage of TherapeuticsMD with an Outperform rating and Price Target of $13, based on an NPV analysis of the
pipeline. Three product approvals were granted by the FDA in 2018 providing a
solid foundation for the company to become a significant player in the
women’s health space. - Strong Player in Women’s Health. Three product approvals granted in 2018 include; i) Imvexxy
for patients with vulvovaginal atrophy (VVA), ii) Bijuva (estradiol and
progesterone) to treat vasomot…
Get full report on Channelchek desktop.
*Analyst
certification and important disclosures included in full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.